烷化组蛋白去乙酰化酶抑制剂在实验性MPO-ANCA血管炎中可能具有治疗价值
研究在两种MPO-ANCA血管炎啮齿动物模型中评估烷化融合组蛋白去乙酰化酶抑制剂EDO-S101的疗效。小鼠被动模型预处理未预防肾小球肾炎,但大鼠主动模型治疗显著减轻肾小球肾炎和肺出血,并耗竭B/T细胞、诱导增殖人B细胞DNA损伤和凋亡,提示其可能通过调节适应性免疫发挥作用。
要点
- EDO-S101在大鼠MPO-ANCA显微镜下多血管炎模型中显著减轻肾小球肾炎和肺出血。
- EDO-S101预处理未能预防小鼠被动IgG诱导的肾小球肾炎。
- EDO-S101耗竭大鼠B/T细胞并诱导增殖人B细胞DNA损伤和凋亡。
核心结论
- EDO-S101可能通过主要作用于针对自身抗原MPO的适应性免疫应答,在ANCA相关血管炎治疗中发挥作用。
研究设计与样本
- 研究在两种已建立的ANCA相关血管炎啮齿动物模型中进行:小鼠被动抗MPO IgG诱导肾小球肾炎模型和大鼠主动MPO-ANCA显微镜下多血管炎模型。
主要发现
- 小鼠预处理EDO-S101减少循环白细胞,但未预防被动IgG诱导的肾小球肾炎。
- 大鼠治疗EDO-S101显著减轻肾小球肾炎和肺出血。
- EDO-S101显著耗竭大鼠B细胞和T细胞。
- EDO-S101诱导增殖人B细胞DNA损伤和凋亡。
临床怎么用
- EDO-S101可能作为ANCA相关血管炎的潜在治疗选择,尤其针对适应性免疫应答,但需进一步临床研究验证。
局限性
- 研究仅基于啮齿动物模型,尚未在人体中验证疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Current therapies for treating antineutrophil cytoplasm autoantibody (ANCA)-associated vasculitis include cyclophosphamide and corticosteroids. Unfortunately, these agents are associated with severe adverse effects, despite inducing remission in most patients. Histone deacetylase inhibitors are effective in rodent models of inflammation and act synergistically with many pharmacological agents, including alkylating agents like cyclophosphamide. EDO-S101 is an alkylating fusion histone deacetylase inhibitor molecule combining the DNA alkylating effect of Bendamustine with a pan-histone deacetylase inhibitor, Vorinostat. Here we studied the effects of EDO-S101 in two established rodent models of ANCA-associated vasculitis: a passive mouse model of anti-myeloperoxidase IgG-induced glomerulonephritis and an active rat model of myeloperoxidase-ANCA microscopic polyangiitis. Although pretreatment with EDO-S101 reduced circulating leukocytes, it did not prevent the development of passive IgG-induced glomerulonephritis in mice. On the other hand, treatment in rats significantly reduced glomerulonephritis and lung hemorrhage. EDO-S101 also significantly depleted rat B and T cells, and induced DNA damage and apoptosis in proliferating human B cells, suggesting a selective effect on the adaptive immune response. Thus, EDO-S101 may have a role in treatment of ANCA-associated vasculitis, operating primarily through its effects on the adaptive immune response to the autoantigen myeloperoxidase.
引用
- Dooley D, van Timmeren MM, O'Reilly VP, et al. Alkylating histone deacetylase inhibitors may have therapeutic value in experimental myeloperoxidase-ANCA vasculitis. Kidney Int. 2018. PMID: 30158055. doi:10.1016/j.kint.2018.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。